Long‐term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low‐dose IMRT salvage12. Issue 4 (19th September 2012)

• Record Type: Journal Article
• Authors: Berry, Jesse L.; Jubran, Rima; Kim, Jonathan W.; Wong, Kenneth; Bababeygy, Simon R.; Almarzouki, Hashem; Lee, Thomas C.; Murphree, A. Linn
• Is Part Of: Pediatric blood & cancer. Volume 60:Issue 4(2013:Apr.)
• Page Start: 688
• Page End: 693
• Publication Date: 2012-09-19
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.24303
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>Background</title> <p>To evaluate outcomes of Group D eyes of bilateral retinoblastoma patients treated with primary chemoreduction and external beam radiation as salvage.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>Procedure</title> <p>Retrospective chart review of patients diagnosed with bilateral retinoblastoma and designated Group D in at least one eye from January 1, 2000 to December 31, 2009. Overall, 62 Group D eyes of 49 patients were included; 13 had bilateral Group D disease. Primary chemoreduction with vincristine, etoposide, and carboplatin with local consolidation was administered, followed by external beam radiation in the form of intensity‐modulated radiation therapy (IMRT) as salvage for recurrent tumor. Primary outcome measure was globe salvage.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>Results</title> <p>Of 62 Group D eyes, 7 were enucleated primarily; 55 were treated with systemic chemoreduction, and local therapy. Chemoreduction cured 26 of 55 eyes (47%). Recurrences were found in 29 eyes; 5 underwent enucleation and 24 were treated with IMRT at a dose of 24 Gy (2 eyes) or 36 Gy (22 eyes). Of the 24 irradiated eyes, 19 (79%) were salvaged and 5 required enucleation. Final visual acuity ranged from 20/20 to light perception with 10 eyes having 20/80 or better visual acuity. Average follow‐up was 54.2 months.</p> </sec> <sec id="abs1-4" sec-type="section"> <title>Conclusion</title> <p>Kaplan–Meier estimates of eye survival of Group D eyes in bilateral patients at 12 months is 82% (95% confidence interval [CI] 70.1–89.7%); at 60 months eye survival is estimated to be 68% (95% confidence interval [CI] 55.4–82.8%). Systemic treatment for retinoblastoma demonstrated a high rate of globe preservation with acceptable complications and many eyes retaining functional vision. Pediatr Blood Cancer 2013; 60: 688–693. © 2012 Wiley Periodicals, Inc.</p> </sec> </abstract>